CinCor Pharma, Inc. (CINC)

NASDAQ: CINC · IEX Real-Time Price · USD
16.15 0.15 (0.94%)
Jan 25, 2022 9:45 AM EST - Market open
Market Cap589.78M
Revenue (ttm)n/a
Net Income (ttm)-26.83M
Shares Out36.52M
EPS (ttm)-0.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,760
Open18.34
Previous Close16.00
Day's Range16.10 - 16.15
52-Week Range13.01 - 18.99
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CINC

CinCor Pharma is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. We are conducting a Phase 2 clinical trial of CIN-107 in patients whose blood pressure is not controlled despite treatment with three antihypertensive agents and have recently initiated a separate Phase 2 clinical trial in patients with elevated aldosterone levels whose blood pressure is not controlled despite treatment with one antihypertensive agent. In addit...

IndustryBiotechnology
IPO DateJan 7, 2022
CEOMarc de Garidel
Employees10
Stock ExchangeNASDAQ
Ticker SymbolCINC
Full Company Profile

Financial Performance

Financial Statements

News

CinCor Pharma Appoints June Lee to Its Board of Directors

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company's Board of Directors. Dr. Lee brings ...

1 week ago - GlobeNewsWire

10 Best Stocks to Buy on the Nasdaq Right Now

With the technology-centric Nasdaq having a rough time of things, this sets up possible attractive discounts for stocks to buy. The post 10 Best Stocks to Buy on the Nasdaq Right Now appeared first on I...

1 week ago - InvestorPlace

CinCor Pharma's stock opens well above IPO price, then sells off sharply

CinCor Pharma Inc.'s stock CINC, +0.22% shot out of the gate in morning trading Friday, but then pulled back sharply, to trade briefly below in negative territory. The Massachusetts-based biopharmaceuti...

2 weeks ago - Market Watch

CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range

CinCor Pharma Inc. CINC, is set to go public on the Nasdaq Friday, after the Massachusetts-based biopharmaceutical company's upsized initial public offering priced overnight at $16 a share, in the middl...

2 weeks ago - Market Watch

CinCor Pharma Announces Pricing of Initial Public Offering

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the tr...

2 weeks ago - GlobeNewsWire

CinCor Pharma sets IPO terms, as the biotech looks to raise up to $187 million

CinCor Pharma Inc. CINC, +0.73% has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company focusing on treatments of hypertension, could be valued at up to...

3 weeks ago - Market Watch

CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hype...

3 weeks ago - GlobeNewsWire